Nevertheless, due to rapid changes in the standard of care in metastatic NSCLC wherein immune checkpoint inhibitor therapy is now incorporated in the frontline setting, the current phase II protocol will address this limitation and is amended to study pembrolizumab in combination with CIMAvax-EGF as first-line treatment in NSCLC patients with PD-L1 TPS ≥50%. Here, EGF is linked to non-small cell lung carcinoma.